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Galectin-8 (gal-8) is a “tandem-repeat”-type galectin, con-
taining two carbohydrate recognition domains connected
by a linker peptide. gal-8 is expressed both in the cytoplasm
and nucleus in vascular endothelial cells (ECs) from normal
and tumor-associated blood vessels, and in lymphatic endo-
thelial cells. Herein, we describe a novel role for gal-8 in the
regulation of vascular and lymphatic angiogenesis and pro-
vide evidence of its critical implications in tumor biology.
Functional assays revealed central roles for gal-8 in the
control of capillary-tube formation, EC migration and in
vivo angiogenesis. So far, two endothelial ligands have been
described for gal-8, namely podoplanin in lymphatic vessels
and CD166 (ALCAM, activated leukocyte cell adhesion mol-
ecule) in vascular ECs. Other related gal-8 functions are
also summarized here, including cell adhesion and migra-
tion, which collectively demonstrate the multi-functionality
of this complex lectin. Thus, gal-8 is an important compo-
nent of the angiogenesis network, and an essential molecule
in the extracellular matrix by providing molecular anchor-
ing to this surrounding matrix. The implications of gal-8 in
tumor angiogenesis remain to be further explored, but it is
exciting to speculate that modulating gal-8-glycan interac-
tions could be used to block lymphatic-vascular connections
vital for metastasis.
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Introduction
Galectin 8 (gal-8) is a member of the evolutionary conserved
family of galectins, which share a high affinity for β-galactosides
(Barondes et al. 1994). gal-8 contains two canonical carbohy-
drate recognition domains (CRDs) joined by a linker peptide
(Bidon-Wagner and Le Pennec 2004; Zick et al. 2004). gal-8 was
initially cloned from a rat liver cDNA library, and the resulting
protein is composed of 316 amino acids (35 kDa) with two
CRDs. These N- and C-terminal domains share 35% homology
and both contain sequence motifs conserved among most CRDs
of galectins (Hadari et al. 1995). A human homolog gene, called
prostate carcinoma tumor antigen-1 (PCTA-1), was detected by
screening a cDNA expression library of the human LNCaP cell
line derived from advanced prostate cancer (Su et al. 1996;
Gopalkrishnan et al. 2000). Concomitantly, another cDNA en-
coding for a human gal-8 was also isolated from a human brain
hippocampus library, which shares 97% homology at the protein
level with PCTA-1 (Hadari et al. 1997).
The human gal-8 gene (LGALS8) was shown to encode
seven different isoforms, resulting from alternative splicing.
The corresponding mRNAs encode for three isoforms that
belong to the tandem-repeat galectin group (with two CRDs)
and the others to the prototype group (possessing one CRD).
The bi-CRD isoforms differ mainly in the size of their hinge
region and have been called according to the length of this
linker peptide as gal-8S (small gal-8, with a short linker
region), gal-8M (medium gal-8, with an intermediate linker
region) and gal-8L (long gal-8, with the longest linker peptide,
Figure 1D). They are produced by alternative splicing at the
level of the linker peptide and untranslated (3′ and 5′UTR)
regions. In fact, three models of splicing have been proposed,
which should be revised as they show some divergences
(Figure 1; Gopalkrishnan et al. 2000; Bidon-Wagner and Le
Pennec 2004; Ahmed et al. 2007). Of note, in the genomic
structure of PCTA-1 (Figure 1C), the two exons at the extrem-
ities are present as partial or complete entities in the mature
message due to internal processing (Gopalkrishnan et al. 2000).
gal-8 isoforms that are prototype galectins, possessing only one
CRD, have not been found at the protein level (Bidon et al.
2001; Bidon-Wagner and Le Pennec 2004; Ahmed et al. 2007).
The amino acid sequence and CRD arrangement of human
gal-8M (middle isoform with 317 amino acids; NP_963837;
NM_201543) is shown in Figure 2; this isoform is a major nat-
urally occurring variant of human gal-8, with a linker peptide
comprising 28 amino acids. In addition, the functional conse-
quences of gal-8 splicing are still poorly understood. Therefore,
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potential biological effects of specific gal-8 splice variants in
EC biology and angiogenesis, which have been demonstrated
for gal-9 (Heusschen et al. 2014), should be evaluated in the
future.
Regarding carbohydrate specificity, both gal-8 CRDs differ
dramatically (Hirabayashi et al. 2002; Ideo et al. 2003; Patnaik
et al. 2006; Carlsson, Oberg, et al. 2007; Stowell et al. 2008),
and both ones are required for different effects, in addition to
the proper length of the linker peptide (Levy et al. 2006). The
N-terminal domain of gal-8 (gal-8N) has much higher affinity
for 3′-O-sialylated-lactose and 3′-O-sulfated-lactose than for
oligosaccharides terminating in Galβ1-3/4GlcNAc. The crystal
structure of gal-8N or gal-8Null (a mutant bi-CRD form of
human gal-8 without linker peptide) in complexes with lactose
and Neu5Acα2-3Galβ1-4Glc (α2-3-sialyl-lactose) revealed that
Arg45, Gln47 and Arg59 residues, which are conserved in the
N-CDR of rat gal-8 and in the N-CRD of all mouse and human
gal-8 isoforms (Tribulatti et al. 2007; Ideo et al. 2011), interact
with the sialic acid or sulfate moieties of 3′-sialyl- and
3′-sulfo-lactose. Arg45 is also conserved in other tandem-repeat
galectins: in human gal-9 N- and C-CRD, which have signifi-
cant affinity for α2-3-sialylated oligosaccharides (Yoshida et al.
2010), and in human gal-4 N-CRD, which binds sulfated
glycans (Ideo et al. 2007, 2011). Amino acids responsible for
Fig. 1. Schematic representations of the genomic structure of gal-8, according to different models of alternative splicing, and the resulting protein isoforms. (A)
Genomic structure showing coding and non-coding regions in both CDRs. Alternative exons are shown hatched. In the linker region, three alternatively spliced
regions have been designated as insertional sequence 1 (IS1), intron IE (IE) and insertional sequence 2 (IS2) (Bidon et al. 2001; Bidon-Wagner and Le Pennec 2004).
(B) Splicing occurs within intron VIII (A–F: alternatively spliced regions of intron VIII; Ahmed et al. 2007). Numbering of exons and/or introns in model B is also
shown below the boxes in models A and C for comparison. (C) The two exons at the extremities in PCTA-1 genomic structure are present as partial or complete
entities in the mature message due to internal processing; different polyadenylation signals have been detected (Gopalkrishnan et al. 2000). (D) gal-8 protein
isoforms detected by western blot in different tissues and cell lines; the thrombin-cleavage site is indicated in the linker peptide of gal-8L (Nishi et al. 2006).
UTR, untranslated region; Ex, exon; i, intron.











strong binding to α2-3 sialylated-lactose are absent in the
gal-8C domain (Ideo et al. 2011; Yoshida et al. 2012; Kumar
et al. 2013).
In fact, gal-8 binding to the cell surface does not require its
fine specificity (Patnaik et al. 2006), but it appears to be
mediated by the combined interaction of the two CRDs with
“second best” ligands of moderate affinity (Carlsson, Oberg,
et al. 2007). In intact bi-CRD isoforms of gal-8, the two
domains act independently of each other in solution, whereas at
a surface they act together. Thus, gal-8 binding and signaling at
cell surfaces can be explained by combined binding of the two
CRDs to low- or medium-affinity ligands, and their highest af-
finity ligands, such as sialylated galactosides, are probably not
required. In conclusion, gal-8 functions require cooperative
interactions between its two CRDs (Carlsson, Oberg, et al.
2007). Of note, a role for gal-8 fine specificity in intracellular
targeting has been found: the binding of gal-8 N-CRD to
sialylated galactosides can determine its intracellular targeting
(Carlsson, Carlsson, et al. 2007). Some sialoglycoproteins
recycle between the plasma membrane and Golgi via an endo-
cytic pathway (Slimane et al. 2000; Potter et al. 2006), and their
interaction with the gal-8 N-CRD might mediate this process.
Thus, gal-8 could be a “driver” (similar to gal-3 and -4;
Delacour et al. 2005, 2006) or a “passenger” in such intracellu-
lar targeting (Carlsson, Carlsson, et al. 2007). In this sense, a
role for gal-8 in promoting coagulation factor V (FV) endocyto-
sis in megakaryocytes has also been described: FV internaliza-
tion is effectively inhibited by an antibody directed against
gal-8, and the reduced expression of gal-8 by siRNA technol-
ogy impairs FV uptake (Zappelli et al. 2012).
Galectin-8 in endothelial cells and serum
To gain insight into the possible function of galectins in endo-
thelial cell (EC) biology, Thijssen et al. (2008) analyzed the ex-
pression of all known human galectins in the endothelium.
Particularly, they determined that gal-8 mRNA is expressed in
quiescent human umbilical vein endothelial cells (HUVECs)
and human microvascular endothelial cell (HMEC) lines (RF24
and EVLc2). Also, they confirmed expression at the protein
level in HUVECs by western blotting, showing three gal-8
bands of 34, 36 and 38 kDa. By immunohistochemistry, the
authors demonstrated a dot-like cytoplasmic staining pattern.
In vivo endothelial expression of gal-8 was observed in colon
and kidney but was undetectable in placenta and liver vessels.
Interestingly, EC activation in vitro, by culturing cells under high
serum concentrations, significantly decreased intracellular gal-8
expression while it increased the expression of the membrane-
bound protein. An altered localization was also observed in
vivo; in normal tissues, gal-8 was found in the cytoplasm but
mainly detectable in the nuclei of ECs. However, in human
colon carcinoma tissues, the number of gal-8-positive ECs
decreased, being this lectin exclusively detected in the nucleus
(Thijssen et al. 2008, 2013).
Interestingly, we also found the presence of three gal-8 iso-
forms (34: gal-8S, 36: gal-8M and 38 kDa: gal-8L; Figure 1D)
in vascular bovine aortic endothelial cells (BAECs) by western
blot. We analyzed gal-8 intracellular localization in BAECs by
immunofluorescence, detecting both cytoplasmic and nuclear
distribution of this lectin. To study the in vivo expression and
localization of gal-8 in blood vessels, we performed immuno-
histochemical studies in paraffin-embedded sections of human
prostate and breast normal versus tumor tissues. Blood vessels
contiguous to normal or tumor prostate tissues showed both
nuclear and cytoplasmatic localization of this lectin. Blood
vessels in breast tissues showed strong nuclear staining and
diffuse cytoplasmic reactivity. In conclusion, gal-8 is localized
both in cytoplasmic and nuclear compartments of normal and
tumor-associated ECs from human prostate and breast tissues
(Delgado et al. 2011). In addition, gal-8 has been found to be
highly expressed in human primary dermal lymphatic endothe-
lial cells (LECs), mainly in the cytoplasm. gal-8 mRNA and
protein levels were significantly higher in LECs than in human
primary dermal vascular endothelial cells (BECs); moreover,
two bands (isoforms) reactive with anti-gal-8 antibody were
detected in LECs and BECs by western blot (Cueni and Detmar
Fig. 2. Protein sequence alignments of the human gal-8M isoform (gal-8M). The sequence cloned in the expression vector pET-3a-gal8 (Delgado et al. 2011) is
compared with human gal-8M (GenBank: NM_201543; NP_963837), a middle isoform of gal-8: the four different amino acids are marked with &. Conserved
amino acids between galectins are shown in bold. Amino acids which play key roles in glycan interactions are marked with * for gal-8N and are indicated with # for












2009). Collectively, these results suggest that gal-8 expression
and localization control the biology of blood and lymphatic
vessels.
In serum, gal-8 levels were analyzed in patients carrying dif-
ferent tumors versus healthy individuals. Serum gal-8 concen-
trations were 1.8-fold higher in patients with colorectal cancer
and 5.6 higher in those with metastases with respect to healthy
individuals, as measured by ELISA (n = 51). Similarly, the con-
centrations of gal-8 were 1.8-fold higher in sera from patients
with breast cancer as compared with healthy individuals
(n = 40; Barrow et al. 2011).
Galectin-8 role in vascular angiogenesis
Vascular angiogenesis is a fundamental process by which new
blood vessels sprout from pre-existing ones, a process that is
controlled by a relative balance of inducers and inhibitors of
angiogenesis (Folkman and Shing 1992; Folkman 2003). We
demonstrated that recombinant gal-8, when added to Matrigel,
induced the formation of extensive capillary networks in
BAECs from the macrovasculature. In terms of tube length,
gal-8 promoted the formation of 3-fold longer tubules as com-
pared with those observed in negative controls. This effect
relied on protein–glycan interactions as it was prevented by spe-
cific disaccharide inhibitors such as lactose and thiodigalacto-
side (TDG), but not by the unrelated saccharide sucrose.
gal-8-embedded Matrigel also induced the formation of wide-
spread tubular networks by HMECs, demonstrating that blood
vessels belonging to the micro- or macrovasculature can be sti-
mulated by gal-8. When gal-8 was silenced by a specific
siRNA, a reduction in tube length relative to non-silenced cells
was observed after transfection, showing that the endogenous
gal-8 also promoted tubule formation, probably via its secretion
to the Matrigel (Delgado et al. 2011). We also performed in
vivo angiogenesis experiments with Matrigel containing re-
combinant gal-8, vascular endothelial growth factor (VEGF) or
vehicle alone injected in mice. Those plugs containing either
VEGF or recombinant gal-8 showed increased number of ECs
as compared with control Matrigel plugs. Thus, similar to
VEGF, gal-8 promotes angiogenesis in vivo in a dose-dependent
manner. Importantly, in contrast to gal-1, gal-8 was not found to
be up-regulated in vivo in response to anti-VEGF treatment or
following exposure to hypoxic conditions (Croci et al. 2012,
2014). Therefore, galectins can modulate EC biology and angio-
genesis through different mechanisms. Based on the evidence
summarized in the previous section that describes gal-8 expres-
sion in ECs, it can be hypothesized that under angiogenic
stimulatory conditions, gal-8 expression levels in these cells
seem to remain unaltered, but further studies are needed to elu-
cidate the precise mechanisms that control gal-8 expression in
the endothelium.
Putative role of galectin-8 in lymphangiogenesis
Lymphangiogenesis, the process of new lymphatic vessel for-
mation from pre-existing vessels, is used by normal tissues for
development and repair of lymphatic vasculature, whereas
tumors rely on this process for the establishment of lymphatic-
vascular connections that are so vital for metastasis (Pepper and
Skobe 2003; Cueni and Detmar 2006; Ji 2006). gal-8 (but not
gal-1, -2, -3 and -7) was found to specifically interact with
podoplanin (PDPN), a key molecule in LECs, in a human
protein microarray probed with a fusion protein of PDPN ecto-
domain (PDPN-Fc). gal-8 bound to glycosylated PDPN-Fc
expressed by human embryonic kidney HEK293 cells, but did
not associate with unglycosylated PDPN-Fc derived from CHO
ldlD cells, which are not able to produce O-linked carbohydrate
chains, demonstrating that interactions were glycan-dependent
(Cueni and Detmar 2009). LEC-derived PDPN directly inter-
acted with gal-8 when co-immunoprecipitation was performed
in LEC lysates. Furthermore, gal-8 was found to be highly
expressed by LECs, being involved in promoting LEC adhe-
sion and migration. Although gal-8 promoted adhesion and mi-
gration of LECs, it inhibited the formation of tubular-like
structures by LECs when incorporated into a collagen matrix
(Cueni and Detmar 2009; Figure 3).
Other related functions of galectin-8
Cell adhesion
gal-8 behaves as an extracellular matrix (ECM) protein that
positively or negatively regulates cell adhesion, depending on
the extracellular context as well as on cell surface counter-
receptors like integrins (Levy et al. 2001; Zick et al. 2004;
Elola et al. 2007). In the case of human LECs, they firmly
adhered and spread on gal-8 after seeding; however, when
added to the cell culture medium in a soluble form, gal-8
almost completely prevented the adhesion of LECs to any sub-
strate, due to cell aggregation (Cueni and Detmar 2009). In
human ECV304 ECs, adhesion to immobilized gal-8 produced
the initial formation of lamellipodia followed by the appearance
of F-actin microspikes, a phenomenon also observed in CHO-P
and NIH-hIR cells. Moreover, ECV304 cells spread fast on
gal-8, and wortmannin, a phosphatidylinositol-3-kinase (PI3K)
inhibitor, diminished gal-8-induced cell spreading, although
this agent did not affect the spreading on fibronectin. Therefore,
downstream effectors of PI3K selectively regulate cytoskeletal
rearrangements that occur when ECV304 cells adhere to and
spread on gal-8 (Levy et al. 2003).
Regarding cancer cell adhesion to the vascular endothelium,
as circulating gal-8 levels are increased in sera from patients with
colon and breast cancer, the effects of this lectin on cell adhesion
were carefully analyzed (Barrow et al. 2011). Pre-incubation of
human colon cancer HT29-5F7 cells (a clone of HT29 cells with
resistance to 5-fluorouracil) with recombinant gal-8 induced a
dose-dependent increase of colon cell adhesion to HUVECs,
which was inhibited by lactose. gal-8 also induced increased ad-
hesion of HT29-5F7 and SW620 cells to human microvascular
lung endothelial cells (HMVECs-L), but not in the case of HT29
cells. Thus, increased circulating levels of gal-8 might contribute
to promote metastasis. Moreover, gal-8 induced adhesion to vas-
cular endothelium of HBL-100 human breast epithelial cells
transfected with the Thomsen-Friedenreich (Galβ1-3GalNAc)
disaccharide expressed by the cancer-associated transmembrane
mucin protein 1 (MUC1). Thus, gal-8 might promote dissemin-
ation of certain tumor cells by facilitating adhesion to blood vas-
cular endothelium, at least in part via mechanisms involving
Thomsen-Friedenreich/MUC1. Knocking down MUC1 using a











specific siRNA partially abolished gal-8-mediated cell adhesion
to HMVECs-L (Barrow et al. 2011). Furthermore, gal-8 has
been suggested as a metastasis-associated molecule in an ECM
microarray and in vitro adhesion experiments in cells from
murine lung adenocarcinoma. Combinations of fibronectin and
gal-8 promoted cell adhesion profiles that allowed the discrim-
ination of metastatic cell populations from primary tumor cells
(Reticker-Flynn et al. 2012).
Other tandem-repeat galectins also regulate cell adhesion to
the vascular endothelium. Thus, overexpression of gal-9M or
gal-9S isoforms induces up-regulation of E-selectin in LoVo
colon tumor cell and adhesion to HUVECs. Interestingly,
gal-9L overexpression induces down-regulation of E-selectin
expression and it does not result in an increased cell adhesion
to ECs, although it produces an increased adhesion of these
cells to Matrigel (Zhang et al. 2009). This further illustrates that
the effects of a galectin on adhesion depend on which ligands
are available in a given setting (Heusschen et al. 2013). gal-9
was also shown to suppress both attachment and invasion of
different tumor cells in vivo by inhibiting the binding of
adhesive molecules on tumors to ligands of both vascular endo-
thelium and ECM, respectively, resulting in the suppression of
metastasis (Nobumoto et al. 2008).
Cell migration
Regarding EC migration, we demonstrated that immobilized
gal-8 induced the migration of serum-starved ECs in a dose-
dependent fashion. Indeed, ECs that had not been serum-
starved could be stimulated by lower concentrations of gal-8
when cultured in the absence of serum during the migration
period. This pro-migratory effect of gal-8 could be partially
blocked by specific sugars such as lactose and TDG. Thus, in
addition to promoting capillary-tube formation and in vivo
angiogenesis, gal-8 promotes vascular EC migration in a dose-
and glycan-dependent fashion. Next, we performed migration
assays in the presence or absence of anti-CD166 antibodies:
gal-8 promoted BAEC migration as compared with controls,
and anti-CD166 blocked gal-8 effects on EC migration (Delgado
et al. 2011). gal-8 has been involved in promoting primary
Fig. 3. Glycan-dependent interactions of gal-8 in endothelial cells and their microenvironment. gal-8 can act as a dimer or monomer. It interacts with CD166 in
vascular ECs and promotes angiogenesis and migration. In lymphatic ECs, gal-8 promotes adhesion and migration and regulates lymphangiogenesis. PDPN per se
promotes lymphangiogenesis and interacts with a variety of ligands, such as CD44, inducing cytoskeleton rearrangements. CD166 and CD44 also possess soluble












human dermal LEC migration. Thus, in transwell migration
assays, gal-8 significantly enhanced haptotactic migration of
LECs to the lower chamber, when compared with other unre-
lated proteins such as albumin (Cueni and Detmar 2009).
Galectin-8 ligands in ECs
Podoplanin
PDPN is a sialomucin-like transmembrane protein highly
expressed in lymphatic, but not blood vascular cells, which has
emerged as a potential gal-8-binding partner (Cueni and
Detmar 2009). PDPN has a wide variety of functions including
regulation of organ development, cell motility, tumorigenesis
and metastasis (Wicki and Christofori 2007; Astarita et al.
2012). It contributes to polarization and migration of LECs
(Navarro et al. 2011). Some of its interactions with other pro-
teins such as the C-type lectin CLEC-2 (Kato et al. 2008) or
gal-8 (Cueni and Detmar 2009) depend on the carbohydrate
moieties present in its ectodomain (Figure 3). In fact, the exist-
ence of di-sialylated core 1 sugar moieties attached to
O-glycosylation sites in PDPN has been previously reported
(Kaneko et al. 2007). Interestingly, PDPN is required for
CLEC-2-dependent platelet aggregation, but it also seems to
have an intrinsic effect on proliferation or differentiation
(Astarita et al. 2012). Moreover, it has been reported that over-
expression of PDPN promoted breast cancer cell motility in
vitro and lymphangiogenesis in breast carcinoma xenografts
(without affecting primary tumor growth), which altogether
would potentiate metastasis to lymph nodes (Cueni et al. 2010).
CD166
CD166 is a transmembrane glycoprotein belonging to the im-
munoglobulin superfamily, which is involved in homo- and
heterophilic cell interactions and trans-EC migration (Swart
et al. 2005; Weidle et al. 2010). The whole transmembrane
protein CD166 has been reported to interact with itself, with
sCD166 (Ikeda and Quertermous 2004) and with CD6 (Bowen
et al. 1995; Patel et al. 1995). CD166 has been identified as a
glycoprotein composed of β1-6 branched oligosaccharides
(Ochwat et al. 2004) and eight N-glycosylation sites (Weidle
et al. 2010). Interestingly, CD166 was found in several cell types,
including pulmonary microvascular ECs (PMVECs) (Masedunskas
et al. 2006; Ofori-Acquah et al. 2008), HUVECs, human aortic
ECs, human coronary artery ECs and HMVECs-L (Ikeda and
Quertermous 2004). It has been implicated in the modulation of
tube formation in embryonic and adult ECs (Ohneda et al.
2001; Ikeda and Quertermous 2004). In HMVECs, soluble
isoforms of CD166 (sCD166, sALCAM), containing the single
amino terminal Ig-like domain of CD166, were reported. sCD166
significantly enhanced migration of HMVECs, whereas it inhib-
ited tube formation on Matrigel; sCD166 can partially inhibit
CD166–CD166 homophilic interactions due to its ability to
bind to CD166 (Ikeda and Quertermous 2004). We previously
identified CD166 (ALCAM, Swiss-Prot accession #Q9BH13)
as a gal-8 ligand from BAEC lysates, by mass spectrometry.
To confirm whether gal-8 interacts with endogenous CD166,
we performed co-immunoprecipitation experiments using re-
combinant gal-8 and BAEC lysates, demonstrating their direct
association. To evaluate whether CD166 could mediate gal-8-
induced angiogenesis, we carried out tubulogenesis experiments,
preincubating BAECs with or without different anti-CD166 anti-
bodies: anti-CD166 antibodies significantly diminished BAEC
capillary formation induced by gal-8. Thus, CD166, a gal-8
ligand in BAECs, can mediate at least in part the effect of this
lectin on tubulogenesis (Delgado et al. 2011). We also confirmed
the direct interaction between CD166 and gal-8 by surface
plasmon resonance, with an apparent dissociation constant of
Kd = 2 × 10
−6 M, which indicated a specific binding that could
be blocked by β-galactoside carbohydrates. We also observed
that CD166 was localized both at the cell surface and in the cyto-
plasm of BAECs as revealed by flow cytometry. Moreover, in
functional assays, CD166 was demonstrated to mediate at least
part of the pro-angiogenic and pro-migratory effects triggered by
gal-8 in BAECs (Delgado et al. 2011; Figure 3).
Integrins
gal-8 functions as a matrix-associated protein, whose interac-
tions with integrins mediate, at least in part, both its adhesive
and anti-adhesive properties (Levy et al. 2001, 2003). gal-8
binds to a variety of integrins such as α3β1, α6β1, αM and α5,
depending on the cell types (Hadari et al. 2000; Levy et al.
2003; Nishi et al. 2006). In human vascular ECs, integrins α3
and β1, and to a lesser extent α4, have been identified as poten-
tial ligands on immobilized gal-8: quantitative densitometry
revealed that gal-8 bound 26 and 18% of the total α3 and β1
integrins, respectively (Hadari et al. 2000). In LEC lysates, en-
dogenous β1 integrin was pulled-down adding recombinant
gal-8, revealing the direct interaction between both molecules
(Cueni and Detmar 2009; Figure 3).
CD44
CD44 is a multifunctional receptor with extensive N- and
O-glycosylation (Brazil et al. 2013) involved in numerous cell–
cell and cell–ECM interactions, which influences cellular pro-
cesses including adhesion, migration, invasion and survival
(Ponta et al. 2003; Orian-Rousseau 2010). PDPN interacts with
CD44, and this association regulates lamellipodia extension
and promotes directional motility (Martín-Villar et al. 2010).
A specific CD44 variant designated CD44vRA, which was
found in the synovial fluid from rheumatoid arthritis patients,
has been described as a gal-8 ligand. Using surface plasmon
resonance, the specific binding of different CD44 isoforms to
immobilized gal-8 was analyzed, detecting that the binding
affinity of CD44vRAwas the highest (Kd = 5.8 × 10
−9 M), and
it was 5- and 170-fold greater than that of CD44v3-10
(Kd = 2.7 × 10
−8 M) and sCD44 (Kd = 10
−6 M), respectively.
Furthermore, gal-1 and gal-3 exhibited only negligible binding
to CD44. These results suggest that CD44vRA serves as a high-
affinity receptor for gal-8 (Eshkar-Sebban et al. 2007). The
existence of gal-8-mediated interactions between CD44 and
PDPN cannot be ruled out and should be further investigated.
Conclusion
gal-8 is an angiogenesis modulator in vascular and lymphatic
endothelium, which recognizes different ligands in both types











of endothelia. In vascular ECs from the micro- and macrovas-
culature, we demonstrated that gal-8 promotes angiogenesis.
We suggest that CD166 interacts with gal-8 in the vascular
endothelium, and at least partially regulates gal-8-mediated
angiogenesis and migration. Accordingly, CD166 has been
implicated in migration, trans-EC migration, and in homotypic/
homophilic, and heterotypic/heterophilic adhesion in different
models. In LECs, gal-8 promotes cell adhesion and migration
when immobilized onto a surface, but inhibits the formation of
tube-like structures when incorporated into a collagen matrix.
PDPN is a key modulator of the multi-step process by which
the lymphatic vasculature assumes its definitive shape, and it is
a novel glycosylation-dependent partner of gal-8. PDPN by
itself can promote in vivo lymphangiogenesis, and it might
contribute to regulate the effects of gal-8 on LEC adhesion, mi-
gration and lymphangiogenesis. Other essential gal-8 ligands
such as β1 integrins from vascular or lymphatic ECs complete
the scenario. Additional studies will be required to address the
relevance of gal-8/CD166 and gal-8/PDPN interactions in regu-
lating normal and/or pathological vascular or lymphatic angio-
genesis and the signaling mechanisms underlying these effects.
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BAECs, bovine aortic endothelial cells; BECs, human primary
dermal vascular endothelial cells; CRD, carbohydrate recogni-
tion domain; ECs, endothelial cells; ECM, extracellular matrix;
gal-8, galectin-8; gal-8S, small gal-8; gal-8M, medium gal-8;
gal-8L, long gal-8; gal-8C, C-terminal domain of gal-8 or
C-CRD; gal-8N, N-terminal domain of gal-8 or N-CRD;
HMECs, human microvascular endothelial cells; HMVECs-L,
human microvascular lung endothelial cells; LECs, human
primary dermal lymphatic endothelial cells; PDPN, podoplanin;
PCTA-1, prostate carcinoma tumor antigen-1 (gal-8); TDG, thio-
digalactoside; VEGF, vascular endothelial growth factor.
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